<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with <z:mpath ids='MPATH_458'>normal</z:mpath> cytogenetics accounts for approximately 50% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>There are no pathognomonic markers in these cases and the diagnosis rests on cytomorphologic abnormalities in bone marrow and/or peripheral blood </plain></SENT>
<SENT sid="2" pm="."><plain>Affymetrix high-resolution single-nucleotide polymorphism (SNP) genotyping microarrays allow detection of cytogenetically cryptic genomic aberrations </plain></SENT>
<SENT sid="3" pm="."><plain>We have studied 119 low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> [RA] = 22; refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>] = 51; <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>] = 12; refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> with ringed sideroblasts [<z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e>] = 12; <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e> = 16; <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>] = 6) using SNP microarrays to seek chromosomal markers undetected by conventional cytogenetics </plain></SENT>
<SENT sid="4" pm="."><plain>Loss of heterozygosity (LOH) detected by 50K arrays was verified using 250K and 500K arrays </plain></SENT>
<SENT sid="5" pm="."><plain>We demonstrate the presence of <z:mp ids='MP_0008867'>uniparental disomy</z:mp> (UPD) in 46%, deletions in 10%, and amplifications in 8% of cases </plain></SENT>
<SENT sid="6" pm="."><plain>Copy number <z:chebi fb="0" ids="29306">(CN)</z:chebi> changes were acquired, whereas UPDs were also detected in constitutional DNA </plain></SENT>
<SENT sid="7" pm="."><plain>UPD on 4q was identified in 25% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, 12% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> with <z:mpath ids='MPATH_458'>normal</z:mpath> cytogenetics, 17% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, and 6% of <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e> cases </plain></SENT>
<SENT sid="8" pm="."><plain>Univariate analysis showed deletions (P = .04) and International Prognostic Scoring System (IPSS; P &lt; .001) scores correlated with overall survival; however, on multivariate analysis only IPSS scores retained prognostic significance (P &lt; .001) </plain></SENT>
<SENT sid="9" pm="."><plain>We show, for the first time, that SNP microarray analysis in low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients reveals hitherto unrecognized UPD and CN changes that may allow stratification of these patients for early therapeutic interventions </plain></SENT>
</text></document>